Gilead Sciences, Inc. (GILD)

NASDAQ: GILD · Real-Time Price · USD
106.19
-2.31 (-2.13%)
At close: Jun 23, 2025, 4:00 PM
106.13
-0.06 (-0.06%)
After-hours: Jun 23, 2025, 4:06 PM EDT
-2.13%
Market Cap 132.09B
Revenue (ttm) 28.74B
Net Income (ttm) 5.97B
Shares Out 1.24B
EPS (ttm) 4.73
PE Ratio 22.45
Forward PE 13.05
Dividend $3.16 (2.98%)
Ex-Dividend Date Jun 13, 2025
Volume 8,150,570
Open 108.82
Previous Close 108.50
Day's Range 105.35 - 109.44
52-Week Range 66.01 - 119.96
Beta 0.31
Analysts Buy
Price Target 110.17 (+3.75%)
Earnings Date Aug 7, 2025

About GILD

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p... [Read more]

Sector Healthcare
IPO Date Jan 22, 1992
Employees 17,600
Stock Exchange NASDAQ
Ticker Symbol GILD
Full Company Profile

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial Statements

Analyst Forecast

According to 25 analysts, the average rating for GILD stock is "Buy." The 12-month stock price forecast is $110.17, which is an increase of 3.75% from the latest price.

Price Target
$110.17
(3.75% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Gilead Sciences CEO Daniel O'Day on HIV prevention injection approval

Gilead Sciences CEO Daniel O'Day explains why he believes the biopharma's HIV prevention injection Yeztugo, which received approval from the Food and Drug Administration last week, is a "milestone mom...

5 hours ago - CNBC Television

Gilead Sciences CEO on FDA approval of Yeztugo: A milestone moment in the history of HIV

Gilead Sciences chairman and CEO Daniel O'Day joins 'Squawk Box' to discuss the FDA approval of the company's HIV prevention medication, how the twice-yearly antiviral drug Yeztugo works, the importan...

7 hours ago - CNBC Television

AHF: Gilead's Greed Kills Promise of Lenacapavir for HIV Prevention

LOS ANGELES--(BUSINESS WIRE)--AHF: Gilead's Greed Kills Promise of Lenacapavir for HIV Prevention.

4 days ago - Business Wire

Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved Yeztugo® (lenacapavir)—the company's injectable...

5 days ago - Business Wire

FDA approves Gilead's twice-yearly HIV prevention injection, offering a powerful and convenient new option

The Food and Drug Administration approved Gilead's twice-yearly antiviral drug for preventing HIV. The company and some experts say it is a milestone that could help bring the world closer to ending t...

5 days ago - CNBC

US FDA approves Gilead's twice-yearly injection for HIV prevention

The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences' lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents.

5 days ago - Reuters

Should You Buy Gilead Stock At $110?

Despite a recent setback with an FDA clinical hold on its HIV treatment trials (GS-1720 and GS-4182) due to a decrease in CD4+ T-cells, Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performa...

5 days ago - Forbes

Gilead Sciences, Inc. (GILD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 17, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. ("Gilead" or "the Company") ...

6 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Gilead Sciences, Inc. (GILD) and Encourages Stockholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. ("Gilead" or "the Company") ...

7 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Encourages Gilead Sciences, Inc. (GILD) Investors to Inquire about Securities Investigation

NEW YORK CITY, NY / ACCESS Newswire / June 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. ("Gilead" or "the Company") ...

8 days ago - Accesswire

Gilead Sciences: Strong Buy On Pipeline Momentum And Cost Discipline

Initiate Gilead Sciences with Strong Buy/$181 PT, citing disciplined cost base, accelerating pipeline, and robust Q1-25 execution driving margin and EPS outperformance. HIV franchise resilience and up...

8 days ago - Seeking Alpha

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Gilead Sciences, Inc. (GILD) And Encourages Investors to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. ("Gilead" or "the Company") ...

10 days ago - Accesswire

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Gilead Sciences, Inc. (GILD) And Encourages Stockholders to Reach Out

NEW YORK CITY, NY / ACCESS Newswire / June 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Gilead Sciences, Inc. ("Gilead" or "the Company") ...

11 days ago - Accesswire

Gilead Sciences, Inc. (GILD) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript

Gilead Sciences, Inc. (NASDAQ:GILD) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 11:20 AM ET Company Participants Daniel P. O'Day - Chairman & CEO Conference Call Participants...

13 days ago - Seeking Alpha

US FDA places clinical hold on 2 Gilead trials of weekly HIV pill combination

The U.S. Food and Drug Administration has placed a clinical hold on Gilead Sciences' trials testing a combination of two of its experimental HIV treatments, the company said on Tuesday.

13 days ago - Reuters

Final Trade: NVO, CELH, LION, GILD

The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.

Other symbols: CELHNVOLION
13 days ago - CNBC Television

Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug

In February, the U.S. Food and Drug Administration (FDA) accepted Gilead Sciences, Inc.'s GILD New Drug Application (NDA) submissions for lenacapavir — the company's twice-yearly injectable HIV-1 caps...

18 days ago - Benzinga

Gilead Sciences, Inc. (GILD) Jefferies Global Healthcare Conference (Transcript)

Gilead Sciences, Inc. (NASDAQ:GILD) Jefferies Global Healthcare Conference June 4, 2025 11:05 PM ET Company Participants Cindy Perettie - Executive Vice President of Kite Dietmar P. Berger - Chief Me...

19 days ago - Seeking Alpha

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, Medicare patients.

Other symbols: AZNPFEAMGNBMYBNTXMRK
20 days ago - CNBC

Gilead's CAR-T cell therapy shows promise in deadly brain cancer

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent glioblastoma, a rare event for a fatal brain cancer with few treatment opti...

22 days ago - Reuters

Kite Presents New Real-World Data Supporting Use of Potentially Curative Yescarta® in Outpatient Care Setting for Patients with Relapsed/Refractory Large B-Cell Lymphoma at ASCO 2025

SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (Nasdaq: GILD), today announced real-world data evaluating the safety and effectiveness of Yescarta® (axicabtagene ciloleucel) for patient...

22 days ago - Business Wire

Potentially Earn 12%-15% Income: Monthly Options Series (June 2025)

We explain why selling cash-covered puts and covered calls is a relatively safe choice for earning high income. We will discuss how to formulate a sustainable and repeatable income strategy for option...

Other symbols: AMATAPHAVGOBKBMICTASGL
23 days ago - Seeking Alpha

Gilead's Trodelvy, with Keytruda, cuts breast cancer risk by 35% in trial

Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, acc...

Other symbols: MRK
23 days ago - Reuters

Trodelvy® Plus Keytruda® Reduces Risk of Disease Progression or Death by 35% Versus Keytruda and Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) reduced the risk of disease progression...

23 days ago - Business Wire

Focus: Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty

Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding uncertainty over the Trump Admini...

24 days ago - Reuters